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step, images that represent the center of medial compartment
are selected. 2) Then, the image is converted into black-and-
white image. Threshold between black and white is determined
by the software. 3) Lastly, the contour of MFC is extracted and
four parameters are calculated automatically: a) the average
thickness of the subchondral bone plate (ATS: tentative units),
the ratio of the length of upper surface and the lower surface of
the subchondral bone plate (RUL), c) average squared thickness
of the subchondral bone plate (ASTS) and d) standard deviation
of the thickness of the subchondral bone (SDS). The more se-
vere the irregularity becomes the larger ATS, RUL, ASTS and
SDS become. Correlation between those parameters and clinical
score were analyzed using Pearson’s correlation coefficient.
Results: The data of four parameters were as follows. ATS: 3.34
to 16.42 (ave. 7.01), RUL: 0.980 to 1.536 (ave. 1.165), ASTS:
14.63 to 382.21(ave. 69.70) and SDS: 1.258 to 7.991 (ave.
3.504). ATS, RUL, ASTS and SDS were statistically significant
correlation with Lysholm score (p<0.05).
Conclusions: We have concluded that 1) ATS, RUL, ASTS and
SDS could serve as an objective index that indicating disease
severity of OA; 2) pathological state of subchondral bone plate
was one of the biggest factors to determine the severity of OA;
3) ATS, RUL, ASTS and SDS reflected the pathological state of
subchondral bone area; and 4) ATS, RUL, ASTS and SDS could
be a objective determinant when selecting treatment option.
Non-Surgical Treatment of OA
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Purpose: Osteophytes (OST), which develop through endochon-
dral ossification often at sites of adjacent cartilage loss, are key
features of osteoarthritis (OA). OST in the spine are accompa-
nied by OST in peripheral joints and agents that affect OST in
the spine may potentially affect OST elsewhere in the body. We
evaluated the effect of the bisphosphonate alendronate (ALN)
on the progression of radiographic spinal OST in a secondary
analysis of the Fracture Intervention Trial (FIT).
Methods: FIT was a large (n=6463) randomized placebo-
controlled trial evaluating the effectiveness of ALN at 5 mg/d
(1st 2 years) followed by 10 mg/d thereafter vs placebo (PBO)
over 3-4 years (3 for those with prevalent vertebral fractures
(VtFx), 4 for those without one) in preventing osteoporotic frac-
tures in postmenopausal women with prevalent VtFx or low bone
mass. In a random sample of 200 participants, stratified by age
(<65 vs. ≥65) and presence of baseline VtFx, we read baseline
and follow-up lateral spine x-rays for anterior OST (scored 0-3 on
the superior and inferior aspects of each vertebral body) in the
thoracic (T4-T12) and lumbar (L1-L5) spine (ICC for lumbar=0.88
and for thoracic=0.97), blinded to treatment. We calculated the
sum of OST scores from T4 to L5 at baseline and follow-up. We
evaluated the mean difference in change from baseline to fol-
lowup in the summary OST score between treatment arms using
linear regression and performed separate analyses in which we
additionally adjusted for age, BMI, presence of baseline VtFx,
presence of incident VtFx, baseline kyphosis score, and pres-
ence of diabetes at baseline.
Results: The baseline characteristics of the participants were
similar in ALN and PBO arms (Table 1). The mean change in
summary OST score was significantly less in the ALN group com-
Table 1. Baseline Characteristics
Variable ALN (n=84) PBO (n=116)
Age [mean ± SD (range)] 68.5 ± 6.1 (55-79) 66.1 ± 6.4 (55-80)
Age ≥65 [n (%)] 39 (46.3) 55 (47.1)
BMI [mean ± SD] 24.8 ± 4.2 25.3 ± 3.9
Diabetes [n (%)] 4 (4.8) 5 (4.4)
Baseline Vertebral Fracture [n (%)] 50 (59.5) 64 (55.2)
Incident Vertebral Fracture [n (%)] 5 (6.0) 9 (7.8)
Baseline summary OST score
[mean ± SD (range)] 15.7 ± 9.2 (1-52) 15.5 ± 8.8 (2-49)
Table 2. Change in summary OST score
ALN (n=84) PBO (n=116)
Unadjusted change in summary
OST score [mean ± SE] 3.1 ± 0.4 4.8 ± 0.5 P=0.02
Adjusted* change in summary
OST score [mean ± SE] 3.2 ± 0.4 4.8 ± 0.5 P=0.03
*Adjusted for age, BMI, diabetes, baseline vertebral fracture, incident vertebral
fracture, baseline kyphosis score.
pared to the PBO group (p=0.02) (Table 2), indicating that OST
progression was less in the ALN group. The results remained the
same after multivariable adjustment for potential confounders.
There was no evidence of interaction between treatment as-
signment and presence of baseline or incident VtFx (p=0.3 and
0.7 respectively) suggesting that the prevention of VtFx did not
cause the inhibition of OST growth.
Conclusions: In this pilot study of the effect of ALN vs PBO
on progression of spinal OST from a randomized clinical trial in
older women, ALN was associated with less OST progression
than PBO. This suggests a role for bisphosphonates in altering
the process of OST formation which may be due to direct effects
on endochondral ossification processes or on OA.
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Purpose: Intra-articular injection of hyaluronan (HA)-based vis-
cosupplements is a local therapy for the treatment of pain due to
osteoarthritis. HA is a major component of synovial fluid that pro-
vides shock absorption, joint lubrication and cartilage protection
to the joint. The purpose of these studies was to compare the
physical and histological properties of two crosslinked HA-based
visocosupplements. One of them is NASHA (non-animal stabi-
lized hyaluronic acid) which is an epoxy crosslinked product, and
the other is hylan G-F 20, a divinyl sulfone crosslinked product.
The physical properties including rheology and dilution durability
of the products were evaluated. The biological reactivity of the
products was also evaluated using a muscle implant test.
Methods: The rheological properties of the products, such as
modulus, phase angle, rupture stress and viscosity were as-
sessed by the oscillation and viscometry tests of a control stress
rheometer. For the dilution durability test, the products were di-
luted with buffered saline and the rheological properties were
determined for each dilution. The maximum dilution at which the
percent phase angle increase continued to be ≤ 50% was de-
fined as the product’s dilution durability. The biological reactivity
of the two products was compared with high density polyethylene
(HDPE) as a control. The response to each product was eval-
uated macroscopically and microscopically in a rabbit muscle
implant model at 7 days and 4 weeks after implantation.
Results: NASHA showed a much higher modulus, but much
lower rupture stress (Table 1) than hylan G-F 20. Results sug-
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Product Name HA Conc. Elastic Modulus @ 5 Hz Rupture Stress @ 1 Hz Phase Angle @ 5Hz Viscosity @ 1 s-1
(mg/ml) (Pa) (Pa) (degree) (Pa s)
hylan G-F 20 9 100 -140 25 - 40 7 - 9 45 - 60
NASHA 20 400 -1200 4 - 9 13 - 15 30 - 45
Fig. 1. Dilution durability of hylan G-F 20 and NASHA.
gested that NASHA contains hard gel particles with very weak
force between the gel particles. NASHA acts as a two phase
system resulting in a suspension of hard particles in buffer.
This was confirmed from the dilution durability measurement. As
shown in Figure 1, NASHA has very low dilution durability (25%)
compared to hylan G-F 20 (110%). This suggests that NASHA’s
viscoelastic properties degraded at a low level of dilution. In
contrast, hylan G-F 20 behaves like soft particles suspended in
a long-chain viscoelastic polymer solution, and has much bet-
ter tolerance against dilution. In the muscle implantation study,
the two products showed similar tissue reactivity compared to
HDPE at 7 days post implantation. By four weeks, hylan G-F
20 had little or no material remaining at the implantation site
and had a reactivity score similar to the HDPE control. However,
the NASHA had a higher reactivity score than the HDPE control
(NASHA 9.4 vs HDPE 2.3) and is distinctly visible at the implant
site in photomicrographs (Figure 2).
Fig. 2. Photomicrograph of NASHA following 4 weeks of implantation in rabbit
muscle.
Conclusions: From our studies, we conclude that hylan G-F 20 is
a much softer and smoother gel, has better dilution tolerance, and
has less tissue reactivity than NASHA. As a viscosupplement,
hylan G-F 20 is expected to provide better lubrication, shock
absorption (under moderate dilution) and cartilage protection
than NASHA.
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Purpose: To study the effect of avian chondroitin sulfate (CS)
on both the synthesis rate and the molecular size of hyaluronan
(HA) produced by human OA synoviocytes and chondrocytes,
cultured in the presence or absence of interleukin-1β (IL-1β).
To determine in parallel the expression of key-enzymes of HA
synthesis and the CS-induced signaling pathways.
Methods: Synovial cells and articular chondrocytes were ob-
tained from OA patients undergoing hip arthroplasty, and cul-
tured in 10% FCS-containing DMEM with CS (1-100 μg/ml).
The medium was changed every 2 days. After 4 days, culture
medium was replaced with serum free DMEM containing 1%
ITS, with or without IL-1β (1 ng/ml) and then, the incubation
was further continued for 24 or 48 h. At the end of experi-
ments, culture medium was harvested for HA assay, using an
ELISA-like method. Aliquot samples from medium and cell layer
were also collected for HPLC size-exclusion analysis of the HA
produced. RNA was isolated and reverse transcribed to cDNA,
which was then subjected to relative quantitative real-time PCR
(Q-RT-PCR) procedure, using the ABI PRISM 7000 and SYBR
green detection and specific primers for hyaluronan synthases
(HAS) 1, 2 and 3 and UDP-glucose dehydrogenase (UGDH).
RT-PCR data were normalized with GAPDH mRNA and gene
expression relative to control was calculated with the delta delta
cycle to threshold (ddCt) method. Cytoplasmic protein extracts
were prepared and used in Western-blot analysis of ERK1/2.
Results: CS treatment caused a significant increase of HA
production in both synoviocytes and articular chondrocytes. The
effect was dose and time dependent and was observed for
control and IL-1β-treated cultures. In parallel, the mRNA steady-
state levels of the hyaluronan synthases HAS1 and HAS2 were
found to be elevated by CS. Similarly, CS stimulated basal and
IL-1β induced mRNA expression of UGDH in both synoviocytes
and chondrocytes. On the other hand, the expression of HAS3,
which is known to be rather responsible for low-molecular HA
synthesis, was down-regulated by CS in both controls and IL-1β-
treated cultures. Interestingly, the HPLC profile of HA produced in
the presence of CS revealed a greater amount of high molecular
size HA, compared to controls. Furthermore, when combined
with IL-1β, CS caused a reduction of the low molecular weight
HA fractions induced by the cytokine. The signaling pathways
elicited by CS in synoviocytes and chondrocytes are unknown.
Here, we demonstrated that the MAP kinases ERK1/ERK2 were
activated upon CS treatment, suggesting that this pathway could
be implicated in the CS modulation of HA synthesis by joint cells.
Conclusions: CS enhances HA production by articular cells,
with production of high molecular forms of the glycosamino-
glycan, through concomitant increase of UGDH, HAS1, HAS2
and decreased HAS3 expression. The effect is associated with
phosphorylation of ERK1/2 kinases, suggesting a role of this sig-
naling pathway in the mechanism underlying CS action. These
data support the hypothesis that CS, which is clinically used to
improve OA symptoms, can exert a beneficial effect through in-
